ArticleBMC complementary medicine and therapies2025
Revealing the anticancer potential of nano-encapsulated graviola extract on tongue carcinoma (SCC154) cell line: targeting the PI3K/AKT/mTOR pathway (in vitro study).
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraviola emerged as a promising anticancer agent, with nanotechnology enhancing drugs' therapeutic potential. The purpose of this work was to explore graviola extract and its nano-platform's effects on tongue carcinoma (SCC154 cells) in vitro model.
methodsGraviola leaves extract (GLE) was isolated, and its phenolic content was identified. Three nano-formulations (F1-F3) were optimized for GLE delivery, with F1 chosen for its optimal size and stability to synthesize graviola nanoparticles (GNPs). SCC154 cells were split into three groups: group Ι (untreated SCC154 cells), group ΙΙ: SCC154 cells + ethanolic GLE, and group ΙΙΙ: SCC154 cells + GLE encapsulated in a nano-void delivery system (GNPs). In vitro tests assessed cell viability via MTT assay, cell cycle, and apoptosis by flow cytometry, DNA damage using comet assay, and gene expression of the key molecular markers (PI3K, AKT, mTOR, and GSK-3β) by quantitative real-time polymerase chain reaction. Transmission electron microscopic examination of cells was also performed.
resultsGLE and GNPs reduced SCC154 cells' proliferation compared to untreated cells, with GNPs showing significantly higher cytotoxicity. Both treatments also induced apoptosis, arrested the cell cycle, and caused DNA damage with a significant pronounced effect in the GNPs-treated group. Gene expression analysis revealed a substantial decline in PI3K, AKT, mTOR, and GSK-3β in both treated groups relative to the control group, with a significant downregulation in the GNPs-treated group. Ultrastructural examination revealed severe destruction in tongue carcinoma cells of both treated groups, with substantial damage in the GNPs-treated group.
conclusionGNPs showed a better impact than GLE in tongue carcinoma therapy, causing cytotoxicity and apoptosis, potentially through the PI3K/AKT/mTOR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.